Evolving and Improving the Sustainability of Molecular Tumor Boards: The Value and Challenges

Author:

Bartels Marius1ORCID,Chibaudel Benoist2,Dienstmann Rodrigo345,Lehtiö Janne6,Piccolo Alberta7ORCID,Michielin Olivier8,O’Kane Grainne9,Pruneri Giancarlo710

Affiliation:

1. Department of Medical Oncology, Praxis für Onkologie Mönchengladbach, 41066 Mönchengladbach, Germany

2. Department of Medical Oncology, Hôpital Franco-Britannique—Fondation Cognacq-Jay, Cancérologie ParisOuest, 92300 Levallois-Perret, France

3. Oncology Data Science (ODysSey) Group, Vall d’Hebron Institute of Oncology, 08035 Barcelona, Spain

4. University of Vic-Central University of Catalonia, 08500 Vic, Spain

5. Oncoclínicas, São Paulo 04543-906, Brazil

6. Science for Life Laboratory and Karolinska Comprehensive Cancer Center, Department of Oncology and Pathology, Karolinska Institutet, 17177 Solna, Sweden

7. Pathology Unit 2, Department of Diagnostic Innovation, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy

8. Department of Oncology and the Precision Oncology Service, Geneva University Hospital, 1205 Geneva, Switzerland

9. Trinity St. James’s Cancer Institute, St. James’s Hospital, D08 NHY1 Dublin, Ireland

10. Department of Oncology and Hematology-Oncology, University of Milan, 20122 Milan, Italy

Abstract

The increasing volume of information for cancer care, and the evolution of molecularly guided therapies, have increased the need for molecular tumor boards (MTBs), which can integrate such data into personalized treatment plans to improve patient outcomes. However, recommendations for improving the sustainability of MTBs are lacking. A diverse committee of MTB experts was assembled (February–March 2023), with extensive experience in sustainability in healthcare ecosystems. The aim was to identify MTB-related hurdles throughout the patient journey and develop a general framework for MTBs to operate on larger scales locally, nationally, and internationally. The committee identified ten key pillars for sustainable and scalable MTBs, including technical solutions for data integration and visualization, interoperability, learning loops, clinical trial access, legal considerations, criteria for patient testing, decision standardization, making MTBs official bodies for treatment decisions, local leaders, and international networks. The need for scalable frameworks at academic and community levels was recognized, along with integrating MTBs into national health systems to enhance sustainability and ensure optimal treatment decisions. Irrespective of the health ecosystem, the sustainability and scalability of MTBs are essential. Our framework provides guidelines to address this and to help MTBs evolve towards integrated, essential components of the oncology healthcare system.

Funder

F. Hoffmann-La Roche Ltd.

Publisher

MDPI AG

Reference33 articles.

1. Molecular profiling for precision cancer therapies;Malone;Genome Med.,2020

2. From tissue-agnostic to n-of-one therapies: (r)evolution of the precision paradigm;Adashek;Trends Cancer,2021

3. Merck Sharp & Dohme B.V. (2024, March 01). Keytruda (Pembrolizumab). Summary of Product Characteristics. Available online: https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf.

4. Merck Sharp & Dohme Corp (2024, February 01). KEYTRUDA® (Pembrolizumab). Prescribing Information, Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125514s147lbl.pdf.

5. Bayer HealthCare Pharmaceuticals Inc. (2024, March 01). VITRAKVI® (larotrectinib). Prescribing Information, Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210861s010lbl.pdf.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3